glycanbind
epitop
discoveri
led
renaiss
glycobiolog
also
provid
con
tinuou
suppli
carbohydraterel
target
structurebas
design
new
chemic
entiti
mimic
bioactiv
carbohydr
form
novel
class
therapeut
carbohydr
carbohydratederiv
drug
although
carbohydr
play
import
part
vast
array
biolog
process
carbohydr
carbo
hydratederiv
drug
cover
limit
area
world
therapeut
fig
mani
pathophysiolog
import
carbohydrateprotein
interact
yet
exploit
sourc
new
drug
target
one
reason
might
pharmacokinet
drawback
inher
entli
link
carbohydr
result
high
polar
unabl
cross
passiv
enterocyt
layer
small
intestin
prerequisit
oral
avail
addit
system
avail
abl
parenter
administr
carbohydr
suffer
fast
renal
excret
interact
blood
plasma
compon
possibl
plasma
halflif
requir
success
therapeut
applic
achiev
promin
exampl
lowmolecularweight
heparin
deriv
anim
tissu
fondaparinux
arixtra
glaxosmithklin
use
anti
coagul
case
inhibit
centr
chiral
glycan
gener
hemiacet
ring
closur
carbohydr
lead
glycomimet
drug
beat
ernst
john
l
magnani
abstract
carbohydr
abund
natur
product
besid
role
metabol
structur
build
block
fundament
constitu
everi
cell
surfac
involv
vital
cellular
recognit
process
carbohydr
rel
untap
sourc
new
drug
therefor
offer
excit
new
therapeut
opportun
advanc
function
understand
carbohydrateprotein
interact
enabl
develop
new
class
smallmolecul
drug
known
glycomimet
compound
mimic
bioactiv
function
carbohydr
address
drawback
carbohydr
lead
name
low
activ
insuffici
druglik
properti
examin
exampl
approv
carbohydratederiv
drug
discuss
potenti
carbohydratebind
protein
new
drug
target
focus
lectin
famili
consid
way
overcom
challeng
develop
uniqu
class
novel
therapeut
natur
review
drug
discoveri
zanamivir
relenza
oseltamivir
phosphat
tamiflu
miglustat
zavesca
topiram
topamax
voglibos
glustat
miglitol
glyset
acarbos
glucobay
fondaparinux
arixtra
n
r
h
na
r
na
ac
r
h
r
co
na
r
co
na
r
h
dalteparin
sodium
fragmin
sodium
hyaluron
orthovisc
ardeparin
sodium
normiflo
r
h
r
h
ac
r
h
r
co
r
co
r
long
polysaccharid
chain
consist
repeat
sulphat
dissacharid
unit
brush
border
small
int
tine
treatment
diabet
voglibos
basen
glustatvolix
takeda
miglitol
glyset
pfizer
acarbos
glucobayprandaseprecos
bayer
inhibit
viral
neuraminidas
pharyng
mucosa
zanamivir
relenza
glaxosmithklin
oral
avail
requir
paradigm
glycomimet
drug
classic
sens
oseltamivir
tamiflu
gileadroch
start
carbohydr
lead
drug
like
achiev
systemat
elimin
polar
group
meta
bolic
soft
spot
requir
affin
final
design
prodrug
oral
avail
becam
possibl
carbohydratebind
protein
broadli
classifi
lectin
sulphat
glycosaminoglycan
sgag
bind
protein
two
categori
lectin
present
vertebr
famili
intra
cellular
lectin
exampl
calnexin
ltype
ptype
lectin
bind
core
oligosaccharid
structur
involv
glycoprotein
process
qualiti
control
famili
extracellular
lectin
exampl
galectin
ctype
ityp
rtype
lectin
recog
nize
termin
carbohydr
epitop
cell
pathogen
extracellular
lectin
account
molecular
target
investig
current
drug
discoveri
programm
structur
current
approv
drug
trade
name
bracket
includ
glycosidas
inhibitor
prevent
digest
carbohydr
treatment
diabet
voglibos
miglitol
acarbos
prevent
influenza
viru
infect
zanamivir
oseltamivir
sulphat
glycosaminoglycan
function
anticoagul
bind
antithrombin
iii
treatment
thrombosi
fondaparinux
dalteparin
ardeparin
nardoparin
enoxaparin
addit
carbohydratederiv
drug
use
treat
gaucher
diseas
miglustat
epilepsi
topiram
osteoarthr
sodium
hyaluron
threedimension
domain
lectin
bind
carbohydr
common
threedimension
structur
domain
share
carbohydr
structur
lewi
fuc
glcnac
lewi
x
fuc
glcnac
contrast
sgagbind
protein
heterogen
eou
difficult
classifi
abil
recogn
sgag
aris
cluster
cation
amino
acid
unrel
protein
confer
abil
recogn
anion
structur
motif
extend
sgag
chain
typic
variou
sgagbind
protein
interact
sgag
differ
affin
sgag
sequenc
exclus
recogn
singl
sgag
bind
protein
present
promis
drug
candid
lectin
famili
selectin
dendrit
cell
specif
nonintegrin
dcsign
also
known
ctype
lectin
famili
myelin
associ
glycoprotein
mag
also
known
sialic
acid
bind
immunoglobulinlik
lectin
siglec
exampl
ityp
lectin
pai
galactophil
lectin
pail
fucosebind
lectin
paiil
minor
compon
type
fimbria
fimh
repres
bacteri
lectin
hallmark
ctype
lectin
involv
ca
bind
glycan
carbohydr
recognit
domain
crd
wide
rang
biolog
func
tion
intercellular
adhes
serum
glycoprotein
remov
pathogen
recognit
selectin
perhap
intens
studi
mammalian
carbohydratebind
protein
first
di
cover
function
adhes
molecul
well
understood
famili
consist
three
member
eselectin
also
known
pselectin
also
known
lselectin
also
known
compos
ca
depend
crd
epiderm
growth
factor
egf
domain
variou
short
complementlik
consensu
repeat
singl
transmembran
domain
intracel
ular
tail
although
carbohydr
bind
receptor
site
within
crd
neighbour
egf
domain
influenc
bind
affin
specif
three
selectin
overlap
distinct
express
pattern
tempor
spatial
eselectin
express
endotheli
cell
de
novo
pro
tein
synthesi
hour
stimul
inflammatori
mediat
interleukin
tumour
necrosi
pselectin
express
activ
platelet
also
store
weibelpalad
bodi
endotheli
cell
fuse
cell
surfac
activ
lead
express
pselectin
within
minut
lselectin
con
stitut
express
leukocyt
play
major
part
home
traffick
lymphocyt
blood
lymphat
system
three
selectin
bind
common
carbohydr
domain
share
sialyl
le
ax
sialyl
lewi
sle
sialyl
lewi
x
sle
x
interestingli
carbohydr
sequenc
origin
discov
cancerassoci
antigen
prognost
indic
metastat
di
eas
tumour
cell
coat
carbohydr
chain
recogn
migrat
leukocyt
allow
escap
bloodstream
metastas
organ
tissu
lymph
node
bone
marrow
function
bind
sialyl
le
ax
vivo
p
lselectin
requir
addit
interact
neg
charg
sulphat
group
either
carbohydr
chain
adjac
peptid
sequenc
eselectin
requir
function
bind
sialyl
le
ax
glycolipid
glycoprotein
involv
neg
charg
group
sulphat
carboxyl
bind
l
pselectin
led
one
major
pitfal
design
smallmolecul
inhibitor
selectin
wide
rang
structur
divers
neg
charg
molecul
report
bind
p
lselectin
includ
sulphatid
heparin
fucoidan
sulphat
dextran
chondroitin
sulphat
dermatan
sulphat
tyrosin
sulphat
sulphat
hyaluron
acid
sulpho
galabios
rang
molecul
suggest
inhibitori
activ
due
nonspecif
negativecharg
interact
fact
cautionari
public
describ
potent
pselectin
activ
found
trace
contamin
polyanion
ion
exchang
media
use
prepa
ration
sampl
thu
specif
smallmolecul
highli
charg
selectin
antagonist
inhibit
p
l
eselectin
must
care
evalu
diseas
cell
adhes
extravas
cell
bloodstream
migrat
specif
lymphocyt
implic
patholog
selectin
present
attract
therapeut
target
exampl
e
pselectin
shown
mediat
acut
adhes
aggreg
leukocyt
erythrocyt
vasoocclus
crisi
mous
model
sickl
cell
diseas
furthermor
aberr
extravas
cell
bloodstream
hall
mark
mani
inflammatori
diseas
asthma
coliti
arthriti
psoriasi
cancer
tumour
cell
extravas
bloodstream
use
selec
tin
pathway
metastas
mani
solid
tumour
adeno
carcinoma
gastrointestin
pancreat
breast
lung
prostat
cancer
express
high
level
sle
x
sle
express
selectin
ligand
tumour
cell
patient
gastric
colon
cancer
significantli
correl
poor
surviv
cimetidin
tagamet
glaxosmithklin
histamin
receptor
antagonist
also
suppress
vascular
expr
sion
eselectin
markedli
specif
improv
surviv
highrisk
patient
identifi
tumour
express
sle
sle
x
ref
support
use
selectin
therapeut
target
cancer
selectin
ligand
also
report
play
key
part
dissemin
haematolog
cancer
home
leukaem
stem
cell
microdomain
within
bone
marrow
eselectin
constitut
express
bone
marrow
bind
carbohydr
ligand
found
leukaem
stem
cell
adher
microdomain
bone
marrow
leukaem
cell
becom
quiescent
less
su
ceptibl
kill
antiprolif
chemotherapi
drug
cytosin
arabinosid
potent
selectin
antagonist
present
new
therapeut
opportun
treat
diseas
prevent
sequestr
leukaem
cell
bone
marrow
keep
glycomimet
molecular
mimic
function
carbohydr
improv
affin
target
druglik
pharmacokinet
properti
larg
synthet
produc
polym
atom
arrang
mani
branch
subbranch
radiat
central
core
effect
exert
protein
bind
effector
molecul
site
protein
activ
site
bind
site
circul
combin
therapi
selectin
antagonist
like
make
cell
suscept
chemotherapi
exampl
glycomimet
small
molecul
antagonist
selectin
present
mucos
surfac
present
barrier
environ
potenti
suscept
infec
tion
migrat
dendrit
cell
guard
mucos
surfac
captur
microorgan
present
process
antigen
activ
cell
therebi
induc
immun
respons
invad
pathogen
screen
librari
dendrit
cellspecif
mono
clonal
antibodi
inhibit
bind
intercellular
adhes
molecul
adhes
molecul
activ
cell
singl
cell
surfac
protein
discov
dcsign
aminoacid
sequenc
dcsign
ident
previous
describ
hiv
glycoprotein
bind
ctype
lectin
dcsign
express
patrol
dendrit
cell
mucosa
bind
carbohydr
structur
protein
coat
hiv
initi
entri
port
hiv
host
hiv
particl
bound
dcsign
surfac
den
dritic
cell
protect
destruct
blood
migrat
lymph
node
transinfect
cell
ccchemokin
recep
tor
complex
cell
surfac
bind
spe
cific
dcsign
fucos
mannos
residu
higher
affin
specif
fucos
linkag
le
ax
type
oligosaccharid
structur
format
activ
structur
bind
dcsign
occur
ca
depend
manner
addit
hiv
variou
pathogen
hepat
c
viru
dengu
viru
ebola
viru
marburg
viru
coronaviru
caus
sever
acut
respiratori
syndrom
cytomegaloviru
well
bacteria
mycobacterium
tuberculosi
helicobact
pylori
yeast
candida
albican
exploit
dcsign
infect
host
recent
even
parasit
leishmania
spp
schistosoma
mansoni
also
shown
bind
dcsign
fact
differ
pathogen
capit
infect
strategi
make
dcsign
interest
target
therapeut
intervent
studi
bind
transfer
hiv
human
rectal
mucosa
cell
bound
viru
bound
cell
express
dcsign
although
cell
repres
total
mucos
mononuclear
cell
furthermor
dcsignspecif
antibodi
block
hiv
bind
studi
shown
multival
glycoconjug
lewi
x
dmannos
prevent
attach
ebola
herp
viru
dendrit
cell
dcsign
thu
prevent
subsequ
infect
immun
cell
glycomimet
compound
inhibit
dcsign
base
two
lead
structur
first
highmannos
oligosaccharid
second
lfucos
part
lewi
epitop
determin
synthes
pathogen
camouflag
appear
host
tissu
improv
affin
pharmacokinet
properti
natur
occur
antagonist
glycomimet
type
ligand
synthes
highdens
array
unbranch
man
termin
oligosaccharid
bind
dcsign
almost
effect
entir
man
oligosaccharid
ref
therefor
nonreduc
end
man
frag
ment
man
suggest
play
crucial
part
dcsign
recognit
mimic
one
hexos
moieti
replac
cyclohexanediol
deriv
lead
compound
fig
threefold
greater
affin
dcsign
half
maxim
inhibitori
concentr
ic
mm
mm
respect
furthermor
infect
studi
use
vivo
model
ebola
infect
glycomimet
compound
inhibit
infect
dcsignexpress
jurkat
cell
effici
correspond
natur
disaccharid
although
inhibitori
concentr
experi
millimolar
rang
compound
might
use
prepar
highaffin
multival
antagonist
approach
encourag
strong
inhibitori
effect
multival
antagonist
dcsign
bind
ing
observ
dendrit
mannos
conjug
oligolysinebas
oligosaccharid
cluster
similarli
link
cyclo
hexan
carboxyl
acid
compound
mimic
lewi
x
trisaccharid
inhibit
dcsign
twofold
greater
potenc
ic
mm
mm
respec
tive
bind
affin
weak
compound
therapeut
promis
howev
oligosaccharid
display
larg
multi
valent
dendrim
activ
greatli
improv
bio
logic
activ
shown
vitro
although
larg
multival
present
carbohydr
mimic
thereof
rel
simpl
mean
increas
activ
pose
pharmaceut
challeng
term
rout
administr
possibl
side
effect
unwant
immun
respons
classic
approach
discov
dcsign
antago
nist
success
demonstr
screen
larg
librari
small
molecul
autom
assay
format
screen
compound
hit
ic
valu
low
micromolar
rang
identifi
compound
compound
ref
interestingli
structur
hit
bear
resembl
nativ
carbohydr
ligand
oligomannos
lewi
epitop
con
tain
function
group
interact
ca
crd
inhibitori
activ
could
caus
bind
domain
dcsign
lead
alloster
effect
ityp
lectin
famili
carbohydratebind
protein
immunoglobulin
superfamili
includ
siglec
siglec
function
cell
signal
coreceptor
primarili
express
leuko
cyte
mediat
acquir
innat
immun
function
cytoplasm
domain
siglec
contain
immunoreceptor
tyrosinebas
inhibitori
motif
characterist
accessori
protein
regul
transmembran
signal
endocytosi
cell
surfac
receptor
protein
divers
specif
sialosid
ligand
variabl
cytoplasm
regulatori
element
enabl
siglec
carri
uniqu
role
cell
surfac
siglec
broadli
divid
evolutionarili
conserv
group
siglec
also
known
sialoadhesin
siglec
also
known
siglec
also
known
mag
siglec
dynam
extens
tip
axon
support
actin
grow
toward
synapt
target
evolutionarili
conserv
group
show
select
bind
properti
siglec
mag
preferenti
bind
link
nacetylneuramin
acid
siglec
highli
specif
link
contrast
member
siglec
group
promiscu
bind
often
recogn
one
present
comprehens
character
siglec
siglec
regulatori
protein
prevent
activ
immun
system
develop
autoimmun
diseas
mag
protein
block
regener
central
nervou
system
cn
injuri
unlik
peripher
nervou
system
pn
injur
adult
cn
inher
lack
capac
axon
regener
although
neurit
outgrowth
possibl
princip
block
inhibitor
protein
express
residu
myelin
astrocyt
recruit
site
injuri
date
three
major
inhibitor
protein
identifi
reticulon
also
known
nogo
myelin
oligodendrocyt
glycoprotein
mog
mag
three
protein
bind
activ
receptor
locat
surfac
neuron
lead
format
complex
nerv
growth
factor
receptor
ngfr
also
known
activ
rhoarock
rho
associ
coil
coilcontain
protein
kinas
cascad
result
growth
cone
collaps
rhoarock
inhibitori
cascad
also
trigger
complex
form
mag
brain
ganglio
side
especi
ngfr
although
exact
biolog
role
maggangliosid
interact
yet
resolv
system
inhibit
axon
regenera
tion
mag
could
complet
revers
sialidas
treatment
suggest
sialid
glycan
main
axon
ligand
mag
sar
studi
reveal
termin
tetrasaccharid
epitop
galnac
show
superior
bind
mag
compar
termin
trisaccharid
epitop
present
exampl
refin
sar
profil
led
identif
mag
antagonist
improv
affin
least
case
remark
simpl
structur
fig
howev
owe
use
differ
assay
format
difficult
compar
report
affin
compound
variou
ligand
overal
start
lowaffin
tetrasaccharid
lead
structur
compound
ref
bacteri
viral
lectin
colon
subsequ
develop
infecti
diseas
enter
oral
respiratori
bacteria
requir
adhes
host
tissu
grant
substanti
greater
resist
clearanc
kill
immun
factor
bacteriolyt
enzym
anti
biotic
addit
bacteria
better
abl
acquir
nutrient
enhanc
abil
surviv
infect
host
therefor
antiadhes
drug
prevent
adh
sion
pathogen
host
tissu
may
offer
novel
strat
egi
fight
infecti
diseas
alarm
increas
drugresist
bacteri
pathogen
make
search
new
approach
fight
bacteri
infect
essenti
inhibitori
signal
transduc
cytosol
neuron
coreceptor
ngfr
nerv
growth
factor
receptor
also
known
mag
bound
brain
gangliosid
also
transduc
inhibitori
signal
help
ngfr
coreceptor
cytosol
b
brain
gangliosid
highest
affin
mag
replac
inner
sialic
acid
sulphat
produc
compound
led
fourfold
increas
affin
tetrasaccharid
compound
ref
minim
carbohydr
epitop
mag
bind
serv
lead
structur
develop
antagonist
compound
excel
correl
degre
neurit
outgrowth
bind
affin
establish
type
decisionmak
process
use
bacteria
coordin
gene
express
behaviour
accord
local
densiti
popul
quantit
measur
disord
system
chang
heat
divid
absolut
temperatur
entropi
chang
cost
thermodynam
process
nonsugar
compon
remain
hydrolysi
glycosid
antiadhes
agent
bacteri
cidal
less
like
promot
propag
resist
strain
bactericid
agent
antibiot
carbohydr
epitop
surfac
host
cell
use
bacteria
virus
colon
infect
tabl
start
point
search
glycomimet
entri
inhibitor
challeng
antiadhes
therapi
pathogen
possess
gene
encod
sever
type
adhesin
infect
process
may
express
one
adhesin
glycomimet
antagonist
design
inhibit
multipl
adhesin
feasibl
develop
exampl
describ
pseudomona
aeruginosa
p
aeruginosa
part
normal
flora
healthi
adult
becom
deadli
pathogen
individu
immunocompromis
patient
cystic
fibrosi
hospit
critic
ill
patient
increas
percentag
p
aeruginosa
infect
antibiot
resist
adhes
host
cell
pathogen
express
lectin
pail
paiil
lectin
virul
factor
quorum
sens
control
cytotox
primari
epitheli
cell
cultur
low
concentr
inhibit
ciliari
beat
epitheli
cell
explant
nasal
polyp
inhibit
complet
revers
treatment
carbo
hydrat
ligand
lectin
thu
hour
addit
fucos
ciliari
beat
return
normal
frequenc
pail
paiil
tetramer
lectin
requir
ca
carbohydr
bind
crystal
structur
lectin
complex
carbohydr
ligand
resolv
fig
pail
preferenti
bind
termin
dgalactos
presenc
one
ca
ion
wherea
paiil
bind
unusu
strong
micromolar
affin
lfucos
requir
two
ca
ion
pail
paiil
solubl
intracellu
lar
lectin
howev
releas
cell
lectin
caus
bacteria
adher
host
tissu
process
revers
incub
dgalactos
dmannos
respect
nativ
carbohydr
inhibitor
pail
paiil
dgalactos
lfucos
success
use
treat
tobramycinresist
p
aeruginosa
infect
case
report
combin
therapi
tobramycin
dgalactos
lfucos
inhibit
virul
factor
pail
paiil
cure
infant
system
pulmonari
infect
determin
microbiolog
test
screen
glycan
array
consortium
function
glycom
reveal
lewi
trisaccharid
glcnac
high
affin
ligand
paiil
dissoc
constant
nm
reduc
complex
trisaccha
ride
antagonist
glycomimet
base
glcnac
disaccharid
exampl
antagonist
com
pound
synthes
titrat
calorimetri
experi
increas
entropi
cost
upon
bind
detect
result
higher
flexibl
glcnac
compar
lewi
howev
addit
enthalp
interact
origin
network
hydrogen
bond
compens
entrop
penalti
simplif
paiil
antagonist
achiev
bear
heterocycl
sub
stituent
aglycon
synthes
surprisingli
candid
exampl
compound
similar
potenc
lewi
ref
oligoval
form
glcnac
epitop
compound
ref
exhibit
increas
activ
compar
monoval
form
howev
case
effect
modest
per
saccharid
basi
date
multival
explor
dendri
mer
present
lfucos
show
increas
affin
factor
per
saccha
ride
basi
final
prevent
adhes
p
aeruginosa
mediat
simultan
pail
paiil
lectin
hetero
bifunct
ligand
present
dgalactos
lfucos
oligoval
array
compound
ref
smallmolecul
glycomimet
compound
ref
construct
studi
determin
efficaci
compound
mice
surgic
stress
hepa
tectomi
control
group
die
hour
acut
infect
p
aeruginosa
wherea
mice
treat
compound
surviv
fimh
urinari
tract
infect
uti
among
preval
inflammatori
diseas
caus
pathogen
predomin
pathogen
uti
uropathogen
escherichia
coli
upec
caus
infect
otherwis
healthi
peopl
uncompl
uti
healthi
individu
uropathogen
origin
rectal
microbiota
enter
normal
steril
urinari
bladder
urethra
trigger
infect
cystiti
urinari
tract
bacteria
attach
urinari
tract
epithelium
fimbrial
adhes
molecul
avoid
host
defenc
mechan
bound
bacteria
presum
intern
activ
process
similar
phagocytosi
uncompl
uti
effect
treat
oral
antibiot
fluoroquinolon
cotrimoxazol
amoxicillin
clavanul
depend
su
ceptibl
pathogen
involv
howev
recurr
infect
subsequ
antibiot
exposur
result
emerg
antimicrobi
resist
often
lead
treatment
failur
reduc
rang
therapeut
option
urgent
need
effi
cient
costeffect
safe
nonantibiot
therapi
prevent
treat
uti
without
facilit
antimicrobi
resist
inhibit
type
fimbriaemedi
bact
rial
attach
bladder
epithelium
promis
approach
achiev
goal
studi
show
primari
bladder
cell
ligand
upec
attach
event
requir
highli
conserv
fimh
lectin
locat
tip
bacteri
fimbria
structurefunct
analysi
show
residu
fimh
mannos
bind
pocket
invari
across
upec
strain
noncoval
interact
organ
compound
contain
aromat
moieti
two
decad
ago
variou
oligomanno
side
aromat
antagon
type
fimbriaemedi
bacteri
adhes
identifi
two
approach
taken
improv
affin
ration
design
ligand
guid
inform
obtain
crystal
structur
fimh
multival
present
epitop
crystal
structur
fimh
receptorbind
domain
solv
ref
corr
spond
complex
ref
recent
becom
avail
despit
detail
know
ledg
bind
event
attempt
translat
inform
lowmolecularmass
antagonist
report
select
monoval
fimh
antagonist
depict
fig
refer
compound
methyl
compound
bind
millimolar
rang
potent
monoval
antagonist
report
far
compound
bind
nanomolar
affin
report
affin
explain
basi
structur
crd
locat
tip
fimh
protein
fig
first
hydroxyl
group
posit
mannos
form
extend
hydrogen
bond
network
second
entranc
bind
site
form
two
tyrosin
one
isoleu
cine
socal
tyrosin
gate
support
hydro
phobic
contact
aromat
aglycon
antagonist
occur
compound
exampl
establish
energet
favour
interact
tyrosin
gate
lead
substanti
improv
affin
enhanc
affin
achiev
use
oligoval
multival
fimh
antagonist
exampl
compound
solubl
fimh
antagonist
appli
prevent
bacteri
adhes
host
tissu
face
challeng
mechan
forc
result
fluid
flow
commonli
presum
durat
receptorligand
interact
shorten
shear
stress
howev
recent
discov
abil
e
coli
avoid
detach
dramat
increas
shear
stress
consequ
shear
stressenhanc
adhes
e
coli
evad
detach
bodi
surfac
solubl
glycoprotein
peptid
ubiquit
bodi
fluid
exampl
glycoprotein
uromodulin
also
known
tammhorsfal
urinari
glycopro
tein
bind
fimh
thought
function
bodi
defenc
e
coli
infect
basi
simul
thought
forceinduc
separ
fimh
mannos
ligand
caus
conform
chang
bind
pocket
lowaffin
highaffin
conform
instead
applic
competit
antagonist
alloster
antagonist
capabl
stabil
lowaffin
conform
might
lead
success
therapi
although
monoval
oligoval
antagonist
nanomolar
affin
report
data
avail
regard
pharmacokinet
prop
erti
howev
treatment
uti
oral
bioavail
abil
fast
renal
excret
reach
target
urinari
tract
prerequisit
therapeut
success
field
spawn
success
new
therapeut
exampl
monoclon
antibodi
year
effort
requir
understand
uniqu
challeng
inher
link
carbohydr
deriv
drug
develop
basic
skill
specif
knowledg
move
excit
scientif
discoveri
develop
new
class
therapeut
although
anim
lectin
usual
show
high
degre
specif
glycan
structur
singlesit
bind
affin
typic
low
biolog
system
function
affin
often
attain
oligoval
present
crd
either
oligomer
protein
exampl
cholera
toxin
cluster
cell
surfac
exampl
asialoglycoprotein
recep
tor
addit
pharmacokinet
properti
carbohydr
hit
bioavail
plasma
halflif
typic
unsatisfactori
therapeut
applic
final
although
tremend
improv
novel
glycosyl
protocol
solidphas
approach
becom
avail
oligosaccharid
still
manufactur
cumbersom
multistep
synthes
therefor
challeng
mimic
structur
inform
function
carbohydr
com
pound
druglik
characterist
first
step
process
understand
sar
carbohydr
lead
specif
contribut
made
func
tional
group
bind
well
threedimension
present
pharmacophor
base
inform
possibl
identifi
glycomimet
preorgan
bioactiv
conform
adopt
bound
conform
solut
addit
mimic
show
improv
pharmacokinet
properti
particular
improv
bioavail
serum
halflif
minim
toxic
cost
synthesi
past
develop
ment
carbohydratederiv
drug
often
entir
focus
simultan
solv
rip
obtain
differ
assay
yeast
agglutin
adher
cell
line
deriv
human
urinari
bladder
epithelium
guinea
pig
epitheli
cell
well
surfac
plasmon
reson
experi
immobil
fimh
compar
caution
crossrelax
two
nuclei
observ
longitudin
magnet
given
nucleu
second
nucleu
perturb
equilibrium
satur
transfer
differ
nuclear
magnet
reson
spectroscopi
experi
spindiffus
nuclear
overhaus
effect
spread
magnet
throughout
hydrogen
nuclei
receptor
partial
transfer
hydrogen
nuclei
bind
ligand
requir
highprofil
failur
result
notabl
field
selectin
antagonist
nevertheless
ration
design
glycomimet
potenti
reap
reward
rel
untap
sourc
novel
therapeut
widerang
import
biolog
medic
applic
understand
nativ
interact
start
point
ration
design
glycomimet
analysi
bind
characterist
carbohydratecrd
binari
complex
threedimension
structur
lectin
carbohydratelectin
complex
solv
number
therapeut
interest
target
thu
e
p
lselectin
cocrystal
sle
x
pselectin
glycoprotein
ligand
siaload
hesin
cocrystal
lactos
dcsign
cocrystal
pentasaccharid
glcnac
man
ref
hold
valuabl
inform
ration
design
glycomimet
case
structur
yet
solv
homolog
model
gener
case
mag
exampl
detail
insight
bind
event
gain
nuclear
magnet
reson
nmr
experi
exampl
bound
conform
function
carbo
hydrat
ligand
crd
target
lectin
deter
mine
use
transfer
nuclear
overhaus
effect
noe
addit
bind
epitop
identifi
satu
ration
transfer
differ
nmr
spectroscopi
std
nmr
spectroscopi
techniqu
use
studi
interact
carbohydr
ligand
rotaviru
receptor
ref
anticarbohydr
tumour
associ
antibodi
ref
eselectin
mag
overal
transfer
noe
nmr
std
nmr
experi
allow
rapid
insight
bind
char
acterist
carbohydratelectin
interact
replac
least
partial
xray
investig
timeconsum
map
bind
epitop
chemic
mean
enhanc
bind
affin
gener
low
affin
carbohydratelectin
interact
consequ
shallow
bind
site
lectin
lead
high
solvent
access
complex
form
hydrogen
bond
salt
bridg
owe
larg
offrat
k
binari
complex
character
short
dissoci
halfliv
typic
rang
second
shown
selectin
physiolog
ligand
carbo
hydraterecogn
antibodi
sle
ref
mag
antagonist
given
thera
peutic
applic
drugtarget
binari
com
plex
expect
rang
minut
hour
improv
k
glycomimet
compound
mandatori
therapeut
applic
often
mammalian
lectin
undergo
numer
direct
weak
interact
ligand
specif
exampl
interact
sle
x
eselectin
outlin
fig
consist
six
solventexpos
hydrogen
bridg
salt
bridg
produc
complex
one
possibl
approach
improv
affin
pre
organ
antagonist
bioactiv
conform
compens
low
enthalp
contribut
reduc
entropi
cost
bind
eselectin
strategi
success
see
complex
fig
elucid
xray
std
nmr
studi
glcnac
moieti
interact
bind
site
serv
sole
linker
posit
galactos
fucos
moieti
correct
spatial
orient
success
replac
noncarbohydr
link
er
addit
steric
repuls
deriv
properli
place
substitu
linker
moieti
improv
preorgan
core
result
affin
correspond
antagonist
furthermor
preorgan
carboxyl
optim
well
reveal
cyclohexyl
lactic
acid
best
mimic
target
lectin
offer
wellstructur
bind
pocket
free
energi
bind
improv
incorpor
addit
enthalp
contribut
success
exampl
neuraminidas
inhibitor
zanamivir
oseltamivir
influenza
viral
coat
protein
neuraminidas
natur
substrat
correspond
glycal
compound
mimic
transit
state
hydrolyt
reaction
millimolar
micromolar
affin
improv
affin
transit
state
analogu
zanamivir
oseltamivir
result
guanidinium
substitut
posit
enabl
forma
tion
new
salt
bridg
replac
glycerol
side
chain
posit
lead
new
favour
lipophil
interact
induc
fit
fig
final
multival
frequent
occur
natur
lead
tight
bind
situat
univa
lent
proteinligand
bind
weak
recognit
carbohydr
ligand
bacteri
mammalian
lectin
exampl
phenomenon
spe
cific
inhibit
recognit
event
oligoval
ligand
propos
see
exampl
fig
howev
design
tightbind
oligoval
ligand
part
empir
endeavour
tailor
oligoval
wherebi
space
limit
number
tether
branch
match
adja
cent
sugar
bind
site
protein
protein
cluster
potenti
offer
substanti
increas
avid
target
pharmacokinet
unfortun
limit
phar
macokinet
data
report
carbohydr
glycomimet
oral
absorpt
passiv
permeat
membran
barrier
small
intestin
limit
regard
molecular
mass
polar
number
hydrogen
bridg
donor
accep
tor
hydrophil
natur
oligosaccharid
caus
larg
number
hydroxyl
group
charg
sulphat
carboxyl
make
oral
avail
virtual
imposs
therefor
glyco
mimet
design
pharmacokinet
well
pharmacodynam
profil
adjust
possibl
strategi
improv
passiv
absorpt
bioisoter
replac
crucial
group
pro
drug
approach
success
exampl
prodrug
approach
oseltamivir
ester
prodrug
absolut
bioavailabl
oral
admini
tere
prodrug
detect
plasma
within
minut
reach
maxim
concentr
hour
addit
feasibl
use
activetransport
system
abund
intestin
liver
kidney
brain
also
consid
mani
drug
ration
design
deriv
natur
product
absorb
passiv
transport
antibiot
heart
glycosid
fungicid
take
figur
enhanc
affin
carbohydratederiv
drug
affin
carbohydratederiv
drug
improv
preorgan
bioactiv
conform
solut
core
conform
shown
red
sialyl
lewi
x
rang
acid
orient
shown
blue
rang
bioactiv
conform
complex
core
conform
approxim
acid
orient
approxim
degre
preorgan
mimet
bioactiv
conform
shown
complex
correl
affin
b
affin
improv
establish
new
enthalp
interact
comparison
bind
mode
compound
zanamivir
relenza
oseltamivir
tamiflu
neuraminidas
depict
bb
backbon
sc
side
chain
advantag
activ
transport
addit
activ
transport
enforc
ration
design
exampl
incorpor
amino
acid
structur
therebi
creat
substrat
activ
transport
pep
tide
transport
also
known
also
known
success
exampl
valacyclovir
valtrexzelitrex
glaxosmithklin
antivir
drug
use
manag
herp
sim
plex
valin
attach
parent
drug
acyclovir
zovirax
glaxosmithklinebiovail
lead
fivefold
increas
oral
avail
extens
analysi
structur
requir
transport
identifi
numer
analogu
higher
affin
valin
inform
valuabl
improv
oral
avail
glycomimet
usual
short
serum
halflif
rapid
excret
carbohydr
present
addit
challeng
design
glycomimet
drug
degrad
pre
enc
serum
liver
microsom
routin
assay
metabol
stabil
must
incorpor
earli
design
process
glycomimet
organ
anion
cation
transport
system
locat
liver
kidney
respons
activ
excret
circul
organ
anion
transport
famili
recogn
anion
specif
carboxyl
group
connect
hydrophob
ring
struc
ture
activ
metabolit
form
oseltamivir
exampl
glycomimet
drug
serum
halflif
diminish
recognit
remov
oat
system
probenecid
competit
inhibitor
administ
com
binat
oseltamivir
serum
halflif
activ
metabolit
extend
strategi
suggest
extend
suppli
us
govern
stockpil
oseltamivir
case
nation
emerg
respons
pandem
outbreak
influenza
interact
probenecid
specif
transport
assay
examin
earli
develop
glycomimet
contain
charg
group
identifi
structur
element
may
advers
affect
serum
halflif
recent
effort
elucid
complex
function
human
glycom
pool
resourc
tech
nolog
among
academ
centr
led
rapid
influx
discoveri
acknowledg
new
sourc
structur
inform
appar
human
genom
effort
drug
discoveri
review
show
challeng
medicin
chemistri
need
met
develop
druglik
glycomimet
past
effort
field
highlight
drawback
use
nativ
oligosaccharid
drug
typic
pharmacodynam
pharmacokinet
properti
insuffici
therapeut
applic
addit
lack
affin
suffer
low
tissu
permeabl
short
serum
halflif
poor
stabil
glycomimet
design
correct
shortcom
detail
insight
carbohydratelectin
interact
requir
predominantli
provid
recent
progress
nmr
spectroscopi
xray
crystallographi
thu
identif
bound
conform
func
tional
carbohydr
transfer
noe
nmr
allow
design
mimet
pharmaco
phore
preorgan
bioactiv
conform
lead
reduc
entropi
cost
upon
bind
incorpor
addit
bind
site
frequent
lead
hydro
phobic
contact
enhanc
affin
often
achiev
final
knowledg
bind
epitop
obtain
std
nmr
allow
identifica
tion
neglig
replac
function
group
consequ
design
glycomimet
improv
absorpt
distribut
metabol
excret
accomplish
current
principl
ration
design
glycomimet
implement
academ
institut
industri
laboratori
success
exampl
glycomimet
drug
emerg
strategi
develop
design
pave
way
real
ize
potenti
rel
untap
sourc
therapeut
